China Mesalazine Market, by Route of Administration (Oral and Rectal), by Application (Ulcerative Colitis, Crohn's Disease, and Inflammatory Bowel Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) is estimated to be valued at US$ 51.6 Million in 2022 and is expected to exhibit a CAGR of 3.1% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research studies in the country is expected to drive China mesalazine market growth over the forecast period. For instance, according to a research study performed by Tianjin University of Traditional Chinese Medicine, China in March 2020, mesalazine and probiotics were effective and safe treatments for ulcerative colitis. The study suggested that mesalazine and probiotics did not increase the risk of drug use and had high safety.
China Mesalazine Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and consequent lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on China mesalazine market. Mesalazine or 5-aminosalicylic acid is a drug, which is used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Since the first outbreak of coronavirus (COVID-19) in China in December 2019, the infection has grown to become the most serious medical problem. High mortality among patients with numerous overcrowding in intensive care units was an important contributor that exacerbated the COVID-19 disease's impact, and as a result, increased the strain on healthcare systems. Patients with inflammatory bowel disease (IBD) were more vulnerable to opportunistic infections (OIs); as a result, the use of mesalazine increased for the treatment of inflammatory bowel diseases such as ulcerative colitis, etc. According to the data published in National Center for Biotechnology Information in November 2020, throughout the pandemic, the Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD) international registry has helped clinicians and patients in China to better understand outcomes of COVID-19 in patients with IBD. In January 2022, 7,038 cases of COVID-19 from 74 countries had been reported to determine the impact of IBD treatment regimens on outcomes of COVID-19, including hospitalization and severe COVID-19.
China Mesalazine Market: Key Developments
Initiating research and development activities such as clinical trials for the treatment of Crohn’s disease is anticipated to boost the market growth over the forecast period. For instance, in January 2022, Sixth Affiliated Hospital, Sun Yat-sen University, China initiated the randomized controlled clinical study of the drug mesalazine to evaluate the efficacy of mesalazine combined with biologics in the treatment of moderate to severe conditions of Crohn’s disease.
Browse 9 Market Data Tables and 16 Figures spread through 102 Pages and in-depth TOC on “China Mesalazine Market”- Forecast to 2030, China Mesalazine Market, by Route of Administration (Oral and Rectal), by Application (Ulcerative Colitis, Crohn's Disease, and Inflammatory Bowel Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/china-mesalazine-market-5371
Moreover, increasing adoption of strategies such as collaboration by key market players is expected to drive China mesalazine market growth over the forecast period. For instance, in 2022, Hong Kong Winhealth Pharma Group (Winhealth Pharma), a China-based global innovative biomedical company, and FERRING B.V., a pharmaceutical company, entered into a strategic collaboration on Pentasa (mesalazine) which is used to treat a type of bowel disease known as ulcerative colitis. As a result of this collaboration, Winhealth Pharma obtained the joint promotion rights of Pentasa in the Mainland Chinese market to promote and distribute Pentasa in China.
Key Takeaways of the China Mesalazine Market:
- Increasing prevalence of ulcerative colitis, inflammatory bowel disease, and Crohn’s disease among the Chinese population is expected to increase the prescription of mesalazine which will drive the growth of China mesalazine market over the forecast period. For instance, according to an article published in the journal Frontiers in 2020, it was reported that the incidence rate, in China, for all inflammatory bowel diseases was 1.74/100,000, while for Crohn’s disease and Ulcerative colitis, the incidence rates were 0.40/100,000 and 1.18/100,000, respectively. Moreover, according to the same source, approximately 25% of inflammatory bowel syndrome patients were diagnosed under the age of 18 years.
- Among application, the ulcerative colitis segment is estimated to hold a dominant position in China mesalazine market due to the increasing prevalence of ulcerative colitis over the forecast period. For instance, in April 2020, according to the data published in the World Journal of Meta-Analysis, a study was conducted in China for the analysis of ulcerative colitis, which estimated that the prevalence of ulcerative colitis has increased significantly.
- Major players operating in China mesalazine market include Zhejiang Hengkang Pharmaceutical Co. Ltd., Jiangsu Jubang Pharmaceutical Co., Ltd., ALP Pharm Beijing Co., Ltd., Shanghai Pharmaceuticals Holding Co Ltd., Heilongjiang Tianhong Pharmaceutical Co., Ltd., AbbVie Inc., F. Hoffmann-La Roche AG, Takeda Pharmaceuticals Company Limited, GSK Plc., Tillotts Pharma AG, Novartis AG, Salix Pharmaceuticals, FERRING B.V., Viatris Inc., and Dr. Falk Pharma GmbH
